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Alveolar soft-part sarcoma (ASPS) is a rare, distinctive
sarcoma, typically occurring in young patients. Although it
displays a relatively indolent clinical course, the ultimate
prognosis is poor and is often characterised by late
metastases. Recently, our understanding of the genetic
events underlying the pathogenesis of ASPS has greatly
increased. The historical, histopathological, ultrastructural,
immunohistochemical and genetic aspects of ASPS are
reviewed in this article.
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A
lveolar soft-part sarcoma (ASPS) is a rare,
distinctive sarcoma, typically occurring in
young patients. Despite a relatively indo-
lent clinical course, the prognosis is poor and is
often characterised by late metastases. Since its
formal description by Christopherson et al at
Memorial Sloan Kettering Cancer Center, New
York, USA,
1 ASPS has been the subject of
considerable interest for pathologists and clin-
icians, owing to its unique microscopic features,
uncertain line of differentiation and unpredict-
able clinical behaviour. In the past several years,
our understanding of the genetic events under-
lying the pathogenesis of ASPS has greatly
increased. This article reviews the historical,
histopathological, ultrastructural, immunohisto-
chemical and genetic aspects of ASPS.
HISTORICAL ASPECTS
Credit for the original description of ASPS
traditionally goes to Christopherson, then a
fellow in surgical pathology, working under the
direction of Drs Foote and Stewart.
1 In his
seminal series of 12 cases taken from the
archives of Memorial Sloan Kettering Cancer
Center over a 17-year period, Christopherson et al
coined the descriptive term ‘‘alveolar soft-part
sarcoma’’ for a distinctive and hitherto unrecog-
nised soft-tissue tumour. This tumour typically
occurred in the extremities of young women and
followed a prolonged clinical course with fre-
quent late metastases. It was defined histologi-
cally by the presence of an organoid to
pseudoalveolar pattern and large, eosinophilic
tumour cells. Interestingly, Christopherson et al
noted that several examples of ASPS seemed to
have been previously published under a variety
of other names, including ‘‘malignant myoblas-
toma’’, ‘‘granular cell myoblastoma’’ and ‘‘malig-
nant granular cell myoblastoma’’.
2–6 Although
Christopherson et al did not describe the intra-
cytoplasmic crystalline structures that have
become one of the hallmarks of ASPS, they did
quote an unpublished letter from Pierre Masson
at the very end of their discussion, who noted
that ‘‘trichrome stains show erythrophilic and
cyanophilic inclusions. The latter have in places a
crystalline structure.’’
1 Credit for the seminal
description of these crystals thus belongs to Dr
Masson, who also showed a periodic acid-Schiff
stain of those crystals in his 1956 text, Tumeurs
humaines: histologie, diagnostics et techniques.
7
Apparently unknown to Christopherson and
colleagues, ASPS had been described one year
previously by Smetana and Scott in a series of 14
cases retrieved from the archives of the Armed
Forces Institute of Pathology, as malignant
tumours of non-chromaffin paraganglia. A careful
reading of this study leaves little doubt that the
cases reported by these authors were uniformly
histologically and clinically identical to those later
reported by Christopherson et al.S m e t a n aa n d
Scott chose the term malignant tumours of non-
chromaffin paraganglia because the tumours
resembled non-physiologically active paraganglia,
postulating that primitive paraganglia-like struc-
tures may perhaps normally occur in the somatic
soft tissues (a hypothesis since discredited).
Smetana and Scott also independently noted the
crystals of ASPS, writing that ‘‘within the cyto-
plasm of some of the neoplastic cells were rod-
shaped, coarse, basophilic bodies of unknown
nature …’’.
8
HISTOPATHOLOGICAL FEATURES
ASPS varies little in its appearance from case to
case, and is in some respects remarkable among
soft-tissue neoplasms for the absence of
described variants. As originally described by
Christopherson et al
1 (and by Smetana and
Scott
8), ASPS is characterised by uniform,
organoid nests of polygonal tumour cells, sepa-
rated by fibrovascular septa and delicate capil-
lary-sized vascular channels (fig 1). In these
nests there is prominent cellular dyscohesion,
leading to the distinctive pseudoalveolar pattern
for which it is named. The organoid appearance
may be completely lost and the tumour may be
composed of sheets of epithelioid cells. Tumours
occurring in younger patients and in confined
locations, such as the tongue, often show very
small nests of cells, closely mimicking true
paragangliomas
9 (fig 2). Intravascular tumour
extension is seen in most cases (fig 3). A small
minority of tumours shows unusual features
such as myxoid change, cystic change, haemor-
rhage and a prominent lymphocytic infiltrate
1 8–20
(fig 4).
The cells in the lesion have distinct borders
and abundant eosinophilic to clear, somewhat
Abbreviations: ASPS, alveolar soft-part sarcoma; TFE3,
transcription factor 3
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(fig 5). Clear cell change may be very prominent, closely
mimicking renal cell carcinoma
21 (fig 6). Cross striations and
cytoplasmic fibrils are absent. A characteristic finding is the
presence of periodic acid-Schiff-positive, diastase-resistant
crystalline structures, which may be rhomboid, rod-like or
spiked, in individual, sheaf-like or stacked configurations.
10
These crystals can also be identified with alcian blue and
trichrome histochemical stains. These crystals are not
especially prominent in all cases, and multiple sections may
require careful searching to identify them. ASPS cells
typically have round, regular, eccentrically placed nuclei with
vesicular chromatin and a prominent central nucleolus;
multinucleation may be present in a few cells (fig 7).
Mitotic activity is usually low and necrosis is infrequent.
Although this description applies to most ASPSs, rare cases
may deviate from a typical ASPS by virtue of the presence of
anaplastic-appearing tumour cells with marked variation in
nuclear size.
11 52 0 As noted by Evans,
20 these anaplastic-
appearing foci may also show other atypical features, such as
sheet-like growth, frequent mitotic figures and coagulative
tumour cell necrosis. Extremely rare cases with spindling and
xanthomatous change have also been described.
15 22
Ultrastructural features
The first ultrastructural study on ASPS was that by Shipkey
et al
10 in 1964, with subsequent important studies over the
next 25 years by Font et al,
23 DeSchryver-Kecskemeti et al,
24
Mukai et al
25 and Ordonez et al,
12 among others. ASPS cells
typically rest on an incomplete basement membrane and
contain only rare, primitive cell–cell junctions. The cytoplasm
contains numerous mitochondria and an extensive Golgi
complex with adjacent small dense granules.
10 12 23–25 The
endoplasmic reticulum is usually, but not always, sparse. The
distinctive crystals of ASPS are typically found intermingled
with these dense granules. They are often bounded by a
single membrane and are composed of a periodic latticework
of fibres (diameter 4.5–5 nm and periodicity 10 nm;
fig 8).
10 12 23–25 The composition of these crystals was inter-
preted as a product similar to renin
24 or aggregates of actin
filaments,
25 and it was suggested that they could be similar to
the inclusions seen in rhabdomyoma or nemaline rod
myopathy.
26 However, elegant recent work by Ladanyi et
al,
27 including ultrastructural immunohistochemistry, has
convincingly shown that the crystals consist of aggregates
of the monocarboxylate transporter protein MCT1 and its
cellular chaperone CD147.
27
Figure 1 Low-power view of a typical alveolar soft-part sarcoma,
showing an organoid, pseudoalveolar proliferation of large,
eosinophilic cells and a delicate capillary network.
Figure 2 Low-power view of an alveolar soft-part sarcoma with a
uniform ‘‘small nest’’ pattern. Such cases may easily be mistaken for
paragangliomas.
Figure 3 Intravascular extension in an alveolar soft-part sarcoma
(ASPS); this is present at the periphery of the tumour in nearly all cases
when examined closely, and may account for the high rate of metastasis
seen in the ASPS.
Figure 4 Alveolar soft-part sarcoma with a prominent associated
chronic inflammatory cell infiltrate.
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Until recently, immunohistochemical analysis played a
limited part in the diagnosis of ASPS. Several studies have
examined ASPS immunohistochemically, both with and
without the use of epitope-retrieval techniques, often with
differing results (reviewed by Foschini and Eusebi
28). In
general, ASPSs are negative for epithelial markers, such as
cytokeratins and epithelial membrane antigen, negative for
specific neuroendocrine markers such as chromogranin A
and synaptophysin, and negative for specific melanocytic
markers, such as HMB45 and Melan-A. Non-specific markers
such as neurone-specific enolase and vimentin may be
present in roughly 30–50% of cases. There has been a great
deal of interest in the expression of muscle-related proteins
in ASPS, due to the prevailing theory for many years that
ASPS represented an unusual form of myogenic tumour.
Antibodies to actins in pan, smooth and skeletal muscle have
been reported to be positive in nearly 50% of patients with
ASPS. Actin expression in pan and smooth muscle is by no
means specific for myogenous differentiation, and the ASR-1
antibody to skeletal-muscle actins is notoriously difficult to
interpret becauseof high levelsof non-specific staining.Desmin
expressionhasbeenreportedinaround50%ofcaseswithASPS,
although it tends to be present in only a small number of the
neoplastic cells. Again, it should be emphasised that desmin
expression is not limited to myogenous tumours and can be
seen in a wide variety of other lesions, including melanoma,
tenosynovial giant-cell tumour, Ewing’s sarcoma and angio-
matoid ‘‘malignant’’ fibrous histiocytoma, among others.
21
A much more controversial topic has been whether ASPS
expresses truly specific markers of skeletal muscle differentia-
tion, such as the myogenic nuclear regulatory proteins MyoD1
andmyogenin. In 1991, Rosai et al
29 reported acase of ASPSthat
seemed to show convincing MyoD1 expression by immuno-
fluorescence and western blotting on fresh-frozen tissue.
29 This
was followed by Tallini et al’s
30 report on a MyoD1-positive
ASPS, using immunohistochemistry on frozen sections.
Regrettably, these two early findings have not been substan-
tiated by any subsequent study. Three separate studies, with
commercially available antibodies and modern immunohisto-
chemical techniques, including heat-induced epitope retrieval,
have not identified expression of either MyoD1 or myogenin in
the more than 35 cases studied.
31–33
It has recently been discovered that ASPSs are characterised
by a tumour-specific der(17)t(X;17) (p11;q25) that fuses the
transcription factor 3 (TFE3)g e n ea tX p 1 1t ot h eASPL gene at
17q25, creating an ASPL–TFE3 fusion protein.
34 Recently, an
antibody directed against the C-terminus of the TFE3 has
emerged as a highly sensitive and specific marker of the ASPS
35
(fig 9). Although TFE3 seems to be almost universally expressed
in normal tissues,this expression is at very low levels and strong
nuclear expression of TFE3 is seen almost exclusively in
tumours known to contain the TFE3 gene fusions, such as
ASPSs and rare paediatric renal carcinomas.
35 It must be
emphasised that only nuclear expression of TFE3 is of
diagnostic value, as cytoplasmic staining(possiblynon-specific)
is seen in various tumours. The TFE3 antibody binds to the
protein downstream of exon 4 and therefore is positive in both
fusion variants seen in ASPS. Importantly, however, strong
TFE3 is seen in granular cell tumours,
35 a potentially confusing
and somewhat ironic finding, given the original classification of
ASPS as a ‘‘malignant granular cell myoblastoma’’ (malignant
granular cell tumour).
CYTOGENETIC AND MOLECULAR GENETIC
FEATURES
The earliest cytogenetic analysis of ASPS identified multiple
structural and numerical abnormalities, strongly suggesting a
role for chromosomal abnormalities in the pathogenesis of
Figure 5 High-power view of a typical alveolar soft-part sarcoma,
showing relative cellular uniformity and typical cytological features, with
peripherally placed, vesicular nuclei containing a prominent central
nucleolus.
Figure 6 High-power view of an alveolar soft-part sarcoma, with
uniform clear cell change. This is believed to be an artefact related to
poor cell preservation. However, it may closely simulate metastatic renal
cell carcinoma of conventional subtype.
Figure 7 Multinucleation in an alveolar soft-part sarcoma, a relatively
frequent finding.
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36 Subsequent karyotypes identified transloca-
tions between chromosomes X and 17
37–41 and, in 1998, both
break points were identified: 17q25 and Xp11.2.
42
Subsequently, Ladanyi et al
34 characterised the two genes
concerned in the translocation.
ASPS is characterised by an unbalanced translocation:
der(17)t(X:17)(p11;p25). This translocation results in the
fusion of a gene of unknown function, ASPL, on chromosome
17 to the TFE3 gene on the X chromosome.
34 Consequently,
the ASPL gene is joined in frame upstream of either the third
or fourth exon of TFE3, yielding two fusion variants, type 1
and type 2, respectively (fig 10). Usually, fusion genes are
generated by reciprocal balanced translocations with only one
of the two chimeric genes being pathogenic. The transloca-
tion in ASPS is unusual in that it is unbalanced, although two
patients with a reciprocal translocation have been
described.
34 43 It has been suggested that the female
predominance seen in patients with ASPS is because of the
presence of two X chromosomes in these patients, increasing
their chances of a translocation on this chromosome.
34
ASPL is a ubiquitously expressed protein with greatest
expression in adult heart, skeletal muscle, pancreas and testis,
andsomewhat lower expressioninfetal tissues.
34Although little
is known about the ASPL protein, the gene itself has been
partially characterised: the cDNA is 1872 nucleotides in length,
yielding a predicted protein of 476 amino acids. Sequence
comparison with known human genes has not identified major
homology; however, there is some similarity to sequences from
other species, including yeast, fruit fly and worm;
34 the protein
function is unknown in all of those species. At the structural
level, a sequence homologous to the UBX motif was found in
the C-terminus of ASPL.
34 The UBX domain is an 80-amino acid
module localised in the C-terminus of several eukaryotic
proteins and is hypothesised to have a role in ubiquitin-related
processes.
44 No other complex domains have been identified in
the ASPL sequence.
TFE3 is much more understood: it is one of a family of
basic helix–loop–helix leucine zipper transcription factors
that includes MiTF, TFEB and TFEC.
45 They are ubiquitously
expressed and bind DNA as homodimers and heterodimers.
All possible pairwise combinations have been identified in
vitro, and it has been suggested that tissue-specific gene
expression is regulated by the relative coexpression of each
protein.
45 Two activation domains have been identified in TFE3:
an acidic, N-terminal domain and a proline-rich C-terminal
domain.
46These two domains act synergistically and differential
splicing provides additional regulatory control. The loss of the
N-terminal-activating domain, as is seen in fusion variant 1,
results in a dominant negative form of the transcriptional
activator that interferes with full-length TFE3.
47
The composite ASPL–TFE3 protein loses the ASPL UBX
domain but retains the TFE3 basic helix–loop–helix DNA-
binding domain, leucine zipper dimerisation domain and C-
terminal activation domain. The ubiquitous expression of
ASPL suggests constitutive expression of the ASPL promoter
and, accordingly, it has been hypothesised that the loss of the
TFE3 upstream regulatory elements may contribute to the
pathogenesis of this translocation.
34 In the type 2 fusion, the
N-terminal TFE3-activating domain is lost and, although no
clinical difference has been identified between the two fusion
variants, only a few cases have been analysed.
34 43
Interestingly, TFE3 is partnered with several other genes in
balanced reciprocal translocations in a subset of (usually)
paediatric papillary renal cell adenocarcinomas.
48–52 In these
tumours, several possible translocations can be seen: (1) the
entire coding region of TFE3 is fused with the novel gene
PRCC at 1q21.2 or (2) TFE3 minus the first three exons is
fused to one of two splicing factor genes, PSF at 1p34 or NonO
Figure 8 Electron micrograph, showing a typical intracytoplasmic
crystal in an alveolar soft-part sarcoma (reproduced with the permission
of Dr Cyril Fisher, The Royal Marsden NHS Trust, London, UK).
Figure 9 An alveolar soft-part sarcoma (ASPS) showing uniform,
strong nuclear positivity with an antibody directed against the C-terminus
of transcription factor 3 (TFE3), confirming the presence of an ASPL–
TFE3 fusion protein.
TFE3
ASPL
ASPL_TFE3
type 1
ASPL_TFE3
type 2
5'UT AD bHLH LZ
5'UT UBX 3'UT
bHLH LZ 5'UT 3'UT
3'UT
bHLH LZ 5'UT 3'UT AD
Figure 10 Structure of the alveolar soft-part sarcoma (ASPL), locus
gene transcription factor 3 (TFE3) gene and the ASPL–TFE3 fusion gene.
AD, activation domain; bHLH, basic helix–loop–helix; LZ, leucine zipper;
UT, uridine triphosphate.
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TFE3 type 1 fusion as, in both instances, the TFE3 activation
domain is lost, whereas the basic helix–loop–helix DNA-
binding domain is retained.
CLINICAL FEATURES AND BEHAVIOUR
ASPS is extremely rare, and is generally believed to account
for ,1% of soft-tissue tumours overall.
21 ASPS has, however,
accounted for roughly 10% of cases reported from large
sarcoma referral centres, in both adults
18 and children.
14 As
many as 60% of ASPS cases are seen in women,
18 although
this female sex predilection may be less pronounced in
children.
14 17 The tumour typically occurs in the deep soft
tissues, most often in the buttock and thigh, with a smaller
number of cases at other soft-tissue locations such as the
arm, chest and retroperitoneal tissues.
1 8–20 In children, a
substantial percentage of cases occur in the head and neck,
often in the orbit
23 or tongue.
9 ASPSs have been reported in a
wide variety of locations, including the bladder,
6 stomach,
53
gynaecological tract
54 and bone.
55 Most often, ASPSs present
as painless masses, which may be highly vascular on imaging
studies.
21
ASPS behaves as a relatively indolent, but relentless
sarcoma, characterised by late metastases and an extended
clinical course; survival rates of 77% at 2 years, 60% at
5 years, 38% at 10 years and only 15% at 20 years have been
reported by Lieberman et al.
18 Studies on another large series
from the MD Anderson Cancer Center, Texas, USA, found a
5-year disease-free survival of 71% in patients presenting
with localised disease as compared with only 20% in patients
presenting with metastases.
56 The prognosis for children with
ASPS may be considerably better, with Pappo et al
14 reporting
disease-free survival in 9 of 11 cases (with a relatively short
follow-up duration) and Casanova et al
17 reporting 100%
survival at .5-year follow-up in 12 patients with localised
disease at presentation. Lingual and orbital tumours also
have very high survival rates, possibly reflecting a combina-
tion of small size at the time of diagnosis and younger patient
age.
92 3
No histopathological features are predictive of prognosis in
patients with ASPS, and these tumours should not be graded
under either the National Cancer Institute or French grading
schemes. NCI
57 Features associated with improved prognosis
include younger age at diagnosis, small tumour size and the
presence of localised disease.
18 56 ASPSs most often metasta-
sise to lungs, brain and bone. Metastases, sometimes to
unusual locations such as the breast, may be the presenting
symptom in some patients with ASPS. Adjuvant chemother-
apy does not seem to be effective in the treatment of ASPSs,
although there may be some role for adjuvant radiotherapy in
reducing the risk for local recurrences.
18 56 58
LINE OF DIFFERENTIATION
The cell of origin or, better, line of differentiation taken by
ASPS has been the subject of considerable speculation and
controversy over the past 50 years. ASPS was originally
regarded as a malignant variant of granular cell myoblas-
toma, a term that encompasses the entity now known as
granular cell tumour.
2–6 57 59 60 The speculation that ASPSs
represented unusual malignant tumours of non-chromaffin
paraganglia
8 has subsequently been disproved by several
ultrastructural, histochemical and immunohistochemical
studies, documenting the complete absence of neuroendo-
crine differentiation in ASPS.
25 61 Similarly, the suggestion
that ASPSs were malignant angioreninomas has been
disproved by negative immunohistochemical studies for
renin, as well as by the absence of clinical signs of hyper-
reninism in patients with ASPS.
25 Perhaps the longest lived
hypothesis has been that ASPS is an unusual myogenous
tumour, on the basis of some ultrastructural similarity of a
component of the ASPS crystal to actin filaments,
25 overlap
between the appearance of these crystals and those seen in
nemaline myopathy and rhabdomyoma,
26 and variable
expression of muscle-related proteins, such as actins and
desmin.
28 However, as discussed in the section
Immunohistochemical findings, the specificity and signifi-
cance of these immunohistochemical findings have been
questioned, and there is no convincing evidence of expression
of truly muscle-specific proteins in ASPS.
62
In the light of the recent discovery that ASPS is part of the
family of translocation-associated sarcomas, there exists an
additional hypothesis—that ASPS displays a scrambled
phenotype, without a normal counterpart.
63 This would seem
to be a compelling hypothesis, given the lack of resemblance
of ASPS to any known structure, its resolute defiance of all
attempts to categorise it and our increasing understanding
that a subset of human neoplasms, such as perivascular
epithelioid cell neoplasms, possibly lack normal counter-
parts.
57 Alternatively, it cannot be entirely excluded that
ASPS recapitulates the phenotype of a yet-to-be discovered,
extremely rare, normal cell of unknown function.
DIFFERENTIAL DIAGNOSIS
The differential diagnosis of ASPS is fairly broad, and
revolves around neoplasms that may show nested or
organoid patterns of growth and cells with abundant
eosinophilic cytoplasm. Renal cell carcinomas, adrenal
cortical carcinomas and hepatocellular carcinomas may
mimic ASPS by virtue of their abundant eosinophilic to clear
cytoplasm. Immunohistochemical evidence of strong cyto-
keratin expression, expression of site-associated markers (eg,
renal cell carcinoma antigen in renal cell carcinoma, Melan-A
crossreactivity in adrenal cortical carcinoma and HepPar1 in
hepatocellular carcinoma) and absence of TFE3 expression
should help in this differential diagnosis. Paediatric renal cell
carcinomas with TFE3 gene fusions may show cytokeratin
expression and TFE3 expression to be absent; clinical
correlation as to the presence of a renal mass is critical in
this situation. Malignant melanoma may simulate ASPS, but
should be easily separated immunohistochemically for S100
protein, HMB45 and Melan A. Paragangliomas, unlike
ASPSs, show strong expression of chromogranin A and
synaptophysin. Alveolar rhabdomyosarcoma, despite its
somewhat similar name, appears as an entirely different
‘‘small blue round cell tumour’’, which strongly expresses
desmin and myogenin nuclear regulatory proteins.
Perivascular epithelioid cell neoplasms, such as epithelioid
angiomyolipoma, coexpress smooth-muscle actin and mela-
nocytic markers, and are almost always TFE3-negative. In
most instances, granular cell tumours lack the striking
cytological atypia seen in ASPS and show strong S100
protein expression. TFE3, however, may be expressed by
granular cell tumours, a potential pitfall.
CONCLUSIONS
ASPSs are rare soft-tissue sarcomas with a distinctive and
generally invariable histological appearance. It is now clear
that they are caused by a specific unbalanced translocation,
der(17)t(X:17)(p11;p25), which results in the formation
of an ASPL–TFE3 fusion gene. The presence of this fusion
gene can be detected by either molecular genetics or
immunohistochemical analysis for the C-terminus of the
ASPL–TFE3 fusion protein, assisting in the diagnosis of ASPS
and in its distinction from the wide variety of other
neoplasms with which it may be confused. The presence of
this unique fusion gene also suggests that ASPS lacks a
normal cellular counterpart.
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